Recent years, particularly the COVID-19 pandemic, can be considered a turning point for pharmacovigilance and pharmacoepidemiology in terms of their role in drug safety and drug utilisation monitoring in clinical practice [1]. Researchers operating in the fields of pharmacovigilance and pharmacoepidemiology have extensive knowledge about approved medications, many of which have been or are currently undergoing clinical trials for repurposing. In this context, clinical pharmacologists’ knowledge can be used and translated to optimise dosing and treatment regimens and to assess the relationship between active compound exposure and adverse drug reactions (ADR) or adverse events following immunisation (AEFI), with the crucial aims of optimising drugs or vaccines’ efficacy and ensuring patients’ safety.

Pharmacovigilance and Pharmacoepidemiology as a Guarantee of Patient Safety: The Role of the Clinical Pharmacologist / Crescioli, Giada; Bonaiuti, Roberto; Corradetti, Renato; Mannaioni, Guido; Vannacci, Alfredo; Lombardi, Niccolò. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - ELETTRONICO. - 11:(2022), pp. 3552-3557. [10.3390/jcm11123552]

Pharmacovigilance and Pharmacoepidemiology as a Guarantee of Patient Safety: The Role of the Clinical Pharmacologist

Crescioli, Giada;Bonaiuti, Roberto;Corradetti, Renato;Mannaioni, Guido;Vannacci, Alfredo;Lombardi, Niccolò
2022

Abstract

Recent years, particularly the COVID-19 pandemic, can be considered a turning point for pharmacovigilance and pharmacoepidemiology in terms of their role in drug safety and drug utilisation monitoring in clinical practice [1]. Researchers operating in the fields of pharmacovigilance and pharmacoepidemiology have extensive knowledge about approved medications, many of which have been or are currently undergoing clinical trials for repurposing. In this context, clinical pharmacologists’ knowledge can be used and translated to optimise dosing and treatment regimens and to assess the relationship between active compound exposure and adverse drug reactions (ADR) or adverse events following immunisation (AEFI), with the crucial aims of optimising drugs or vaccines’ efficacy and ensuring patients’ safety.
11
3552
3557
Crescioli, Giada; Bonaiuti, Roberto; Corradetti, Renato; Mannaioni, Guido; Vannacci, Alfredo; Lombardi, Niccolò
File in questo prodotto:
File Dimensione Formato  
jcm-11-03552-v2.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 237.25 kB
Formato Adobe PDF
237.25 kB Adobe PDF Visualizza/Apri

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2158/1287679
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact